Vol. 4 No. 7 (2026), Articles
Vol. 4 No. 7 (2026)

MUKOPOLISAXARIDOZNING ZAMONAVIY DIAGNOSTIKASI VA TERAPEVTIK BOSHQARUVI. MUKOPOLISAXARIDOZ - BOLALARDA UCHRAYDIGAN OGʻIR IRSIY KASALLIK SIFATIDA

Articles
Published 2026-05-05
Saparova Saboxat Izzatillayevna
Navoiy Davlat Universiteti Tibbiyot fakulteti Umumiy tibbiy fanlar kafedrasi o`qituvchisi
Uktamova Zuhra Alisher qizi
Navoiy Davlat Universiteti Tibbiyot fakulteti talabasi
PDF

Keywords

mukopolisaxaridoz, glikozaminoglikanlar, lizosomalar saqlash kasalliklari, fermentlarni almashtirish terapiyasi, gematopoetik stem hujayra transplantatsiyasi, gen terapiyasi, bolalar irsiy kasalliklari, diagnostika, terapevtik boshqaruv.

Abstract

Mukopolisaxaridoz (MPS) lizosomalar saqlash kasalliklarining bir guruhi boʻlib, glikozaminoglikanlar (GAG) parchalanishida ishtirok etuvchi fermentlar etishmovchiligi tufayli yuzaga keladi. Ushbu kasallik bolalarda ogʻir irsiy patologiya sifatida namoyon boʻlib, koʻp tizimli shikastlanishlarga, skelet deformatsiyalariga, yurak-qon tomir, nafas olish, koʻrish va eshitish tizimlarining buzilishlariga olib keladi. Maqolada mukopolisaxaridozning zamonaviy diagnostika usullari, shu jumladan biokimyoviy, molekulyar va tasvirlash metodlari hamda terapevtik boshqaruv strategiyalari, fermentlarni almashtirish terapiyasi, gematopoetik stem hujayra transplantatsiyasi va gen terapiyasi kabi yondashuvlar tahlil qilinadi. Adabiyotlar sharhi va muhokama boʻlimlarida kasallikning epidemiologiyasi, klinik koʻrinishlari va davolash natijalari koʻrib chiqiladi. Natijalar boʻlimida klinik kuzatuvlar va tasviriy materiallar keltirilgan. Xulosa qismida erta diagnostika va kompleks terapiyaning ahamiyati taʼkidlanadi. Tadqiqot maqsadi - mutaxassislar uchun mukopolisaxaridozning zamonaviy boshqaruvi boʻyicha ilmiy asoslangan maʼlumotlar taqdim etishdir.

PDF

References

1. Lipiński, P. (2025). Mucopolysaccharidoses—What clinicians need to know. Biomolecules, 15(10), Article 1448. https://doi.org/10.3390/biom15101448

2. Penon-Portmann, M., Blair, D. R., & Harmatz, P. (2023). Current and new therapies for mucopolysaccharidoses. Pediatrics & Neonatology, 64(Suppl 1), S10–S17. https://doi.org/10.1016/j.pedneo.2023.03.005

3. Sawamoto, K., Chen, H. H., Alméciga-Díaz, C. J., Mason, R. W., & Tomatsu, S. (2018). Gene therapy for mucopolysaccharidoses. Molecular Genetics and Metabolism, 125(1-2), 59–68. https://doi.org/10.1016/j.ymgme.2018.05.016

4. Giugliani, R., Villarreal, M. L., Arash, L., Bjelac, D., & Montaño, A. M. (2021). Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis I. Archives of Disease in Childhood, 106(7), 674–679. https://doi.org/10.1136/archdischild-2020-320473

5. Zuber, Z., & Kieć-Wilk, B. (2023). Diagnosis and management of mucopolysaccharidosis type II. Pediatric Endocrinology Diabetes and Metabolism, 29(3), 184–193. https://doi.org/10.5114/pedm.2023.130000

6. Fraldi, A., Serafini, M., Sorrentino, N. C., Gentner, B., Aiuti, A., & Di Natale, P. (2018). Gene therapy for mucopolysaccharidoses: In vivo and ex vivo approaches. Italian Journal of Pediatrics, 44(Suppl 2), 128. https://doi.org/10.1186/s13052-018-0565-0

7. Sakuru, R., & Bollu, P. C. (2023). Hurler syndrome. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532261/

8. Horgan, C., & Bigger, B. W. (2022). Current and future treatment of mucopolysaccharidosis (MPS) type II: Is brain-targeted stem cell gene therapy the solution for this devastating disorder? International Journal of Molecular Sciences, 23(9), Article 4854. https://doi.org/10.3390/ijms23094854

9. Wood, S. R., & Bigger, B. W. (2022). Delivering gene therapy for mucopolysaccharide diseases. Frontiers in Molecular Biosciences, 9, Article 965089. https://doi.org/10.3389/fmolb.2022.965089

10. Muenzer, J. (2011). Overview of the mucopolysaccharidoses. Rheumatology, 50(Suppl 5), v4–v12. https://doi.org/10.1093/rheumatology/ker394